Passage Bio Stock Performance

PASG Stock  USD 8.61  0.40  4.44%   
On a scale of 0 to 100, Passage Bio holds a performance score of 2. The company holds a Beta of 3.98, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Please check Passage Bio's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Passage Bio's historical price patterns will revert.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(5.18)
Five Day Return
(2.27)
Year To Date Return
(26.35)
Ten Year Return
(98.06)
All Time Return
(98.06)
Last Split Factor
1:20
Last Split Date
2025-07-14
1
Risk Off Will Passage Bio Inc. stock sustain high P E ratios - Quarterly Portfolio Report Free Technical Confirmation Trade Alerts - B NI V
11/26/2025
2
Passage Bio Inc Stock Analysis and Forecast - Institutional Buying Trends Capitalize On Fast Trends - earlytimes.in
12/03/2025
3
Critical Analysis Passage Bio Vir Biotechnology
12/24/2025
4
Passage Bio Trading Down 2.3 percent - Heres What Happened - MarketBeat
01/07/2026
5
Disposition of 5000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3
01/08/2026
6
Passage Bio CEO William Chou Sells 4,076 Shares
01/12/2026
7
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
02/19/2026
Begin Period Cash Flow21.7 M
Total Cashflows From Investing Activities54.9 M

Passage Bio Relative Risk vs. Return Landscape

If you would invest  856.00  in Passage Bio on November 24, 2025 and sell it today you would earn a total of  5.00  from holding Passage Bio or generate 0.58% return on investment over 90 days. Passage Bio is currently generating 0.2961% in daily expected returns and assumes 7.8465% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Passage, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Passage Bio is expected to generate 10.6 times more return on investment than the market. However, the company is 10.6 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of risk.

Passage Bio Target Price Odds to finish over Current Price

The tendency of Passage Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 8.61 90 days 8.61 
about 79.02
Based on a normal probability distribution, the odds of Passage Bio to move above the current price in 90 days from now is about 79.02 (This Passage Bio probability density function shows the probability of Passage Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.98 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Passage Bio will likely underperform. Additionally Passage Bio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Passage Bio Price Density   
       Price  

Predictive Modules for Passage Bio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Passage Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Passage Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.758.6016.45
Details
Intrinsic
Valuation
LowRealHigh
8.4216.2724.12
Details
Naive
Forecast
LowNextHigh
3.3511.1919.04
Details
5 Analysts
Consensus
LowTargetHigh
36.0439.6043.96
Details

Passage Bio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Passage Bio is not an exception. The market had few large corrections towards the Passage Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Passage Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Passage Bio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.05
β
Beta against Dow Jones3.98
σ
Overall volatility
2.85
Ir
Information ratio 0.02

Passage Bio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Passage Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Passage Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Passage Bio had very high historical volatility over the last 90 days
Passage Bio has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0.
Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39.
Passage Bio has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Will CytoMed Therapeutics Limited stock go up in YEAR - 2025 Trade Ideas Low Risk High Win Rate Picks - mfd.ru

Passage Bio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Passage Stock often depends not only on the future outlook of the current and potential Passage Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Passage Bio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares OutstandingM
Cash And Short Term Investments76.8 M

Passage Bio Fundamentals Growth

Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.

About Passage Bio Performance

By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.73)(0.76)
Return On Capital Employed(0.97)(1.02)
Return On Assets(0.73)(0.76)
Return On Equity(1.22)(1.16)

Things to note about Passage Bio performance evaluation

Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Passage Bio had very high historical volatility over the last 90 days
Passage Bio has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0.
Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39.
Passage Bio has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Will CytoMed Therapeutics Limited stock go up in YEAR - 2025 Trade Ideas Low Risk High Win Rate Picks - mfd.ru
Evaluating Passage Bio's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Passage Bio's stock performance include:
  • Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
  • Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Passage Bio's stock performance is not an exact science, and many factors can impact Passage Bio's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Passage Stock analysis

When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios